Andrea Fontana

2.2k total citations
50 papers, 1.0k citations indexed

About

Andrea Fontana is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Andrea Fontana has authored 50 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Andrea Fontana's work include Advanced Breast Cancer Therapies (16 papers), Cancer Treatment and Pharmacology (15 papers) and HER2/EGFR in Cancer Research (14 papers). Andrea Fontana is often cited by papers focused on Advanced Breast Cancer Therapies (16 papers), Cancer Treatment and Pharmacology (15 papers) and HER2/EGFR in Cancer Research (14 papers). Andrea Fontana collaborates with scholars based in Italy, United States and Switzerland. Andrea Fontana's co-authors include Laura de Girolamo, Alfredo Falcone, Romano Danesi, Guido Bocci, Luca Galli, Paola Orlandi, Anna Fioravanti, Teresa Di Desidero, Giacomo Allegrini and Stefania Crucitta and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Cancer.

In The Last Decade

Andrea Fontana

48 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrea Fontana Italy	19	549	335	285	238	153	50	1.0k
Anastasia G Eleftheraki Greece	20	612 1.1×	316 0.9×	357 1.3×	240 1.0×	250 1.6×	37	1.2k
Tyler P. Robin United States	17	608 1.1×	405 1.2×	330 1.2×	198 0.8×	272 1.8×	55	1.3k
Giovannella Palmieri Italy	26	544 1.0×	432 1.3×	364 1.3×	225 0.9×	405 2.6×	113	1.9k
S-A. Im South Korea	18	799 1.5×	454 1.4×	324 1.1×	242 1.0×	87 0.6×	85	1.1k
Lidia Gatto Italy	21	342 0.6×	450 1.3×	326 1.1×	290 1.2×	194 1.3×	83	1.2k
Rüediger Liersch Germany	18	332 0.6×	145 0.4×	438 1.5×	216 0.9×	149 1.0×	33	942
J.P. Delord France	18	706 1.3×	276 0.8×	253 0.9×	162 0.7×	96 0.6×	48	981
Sertaç Yazıcı Türkiye	18	495 0.9×	379 1.1×	459 1.6×	173 0.7×	196 1.3×	56	1.2k
Hyun Jung Jun South Korea	18	617 1.1×	310 0.9×	305 1.1×	202 0.8×	127 0.8×	39	1.2k
Aysegül Ilhan‐Mutlu Austria	20	668 1.2×	712 2.1×	371 1.3×	239 1.0×	229 1.5×	71	1.4k

Countries citing papers authored by Andrea Fontana

Since Specialization

Citations

This map shows the geographic impact of Andrea Fontana's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrea Fontana with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrea Fontana more than expected).

Fields of papers citing papers by Andrea Fontana

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrea Fontana. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrea Fontana. The network helps show where Andrea Fontana may publish in the future.

Co-authorship network of co-authors of Andrea Fontana

This figure shows the co-authorship network connecting the top 25 collaborators of Andrea Fontana. A scholar is included among the top collaborators of Andrea Fontana based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrea Fontana. Andrea Fontana is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blondeaux, Eva, Claudia Bighin, Stefania Russo, et al.. (2024). Abstract PO4-04-05: HER2 immunohistochemistry (IHC) expression in HER2-positive (HER2-pos) metastatic breast cancer (mBC): clinical and prognostic differences between IHC 2+ and IHC 3+ populations. Cancer Research. 84(9_Supplement). PO4–4. 1 indexed citations

Molinelli, Chiara, Marco Bruzzone, Eva Blondeaux, et al.. (2024). The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study. European Journal of Cancer. 213. 115113–115113. 4 indexed citations

Blondeaux, Eva, Claudia Bighin, Stefania Russo, et al.. (2024). Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer. npj Breast Cancer. 10(1). 105–105. 1 indexed citations

Crucitta, Stefania, et al.. (2023). CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients. Cancers. 15(4). 1306–1306. 11 indexed citations

Palazzo, Antonella, Angela Toss, Rossella Graffeo, et al.. (2023). 478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study. Annals of Oncology. 34. S382–S382. 6 indexed citations

Re, Marzia Del, Stefania Crucitta, Claudia Omarini, et al.. (2022). Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib. The Breast. 66. 157–161. 16 indexed citations

Fanelli, Giuseppe Nicolò, Anna Szumera‐Ciećkiewicz, Paola Ferrari, et al.. (2021). Immunohistochemistry for Thymidine Kinase-1 (TK1): A Potential Tool for the Prognostic Stratification of Breast Cancer Patients. Journal of Clinical Medicine. 10(22). 5416–5416. 12 indexed citations

Cantini, Luca, Mirco Pistelli, Filippo Merloni, et al.. (2019). Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients. Clinical Breast Cancer. 20(1). e89–e98. 10 indexed citations

Re, Marzia Del, Andrea Fontana, Stefania Crucitta, et al.. (2018). Correlation of expression of TK1 in plasma-derived exosomes with clinical response to CDK4/6 inhibitors in breast cancer.. Journal of Clinical Oncology. 36(15_suppl). 12037–12037.

10.

Bighin, Claudia, Fabio Puglisi, Lorenzo Gerratana, et al.. (2017). Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study. Annals of Oncology. 28. vi25–vi25. 1 indexed citations

11.

Vrdoljak, Eduard, Norbert Marschner, Christoph Zielinski, et al.. (2016). Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Annals of Oncology. 27(11). 2046–2052. 26 indexed citations

12.

Ghilli, Matteo, Gregory C. Fanelli, Andrea Fontana, et al.. (2016). Carcinosarcoma of the Breast: An Aggressive Subtype of Metaplastic Cancer. Report of a Rare Case in a Young BRCA-1 Mutated Woman. Clinical Breast Cancer. 17(1). e31–e35. 9 indexed citations

13.

Lambertini, Matteo, Arlindo R. Ferreira, Francesca Poggio, et al.. (2015). Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study. The Oncologist. 20(8). 880–889. 22 indexed citations

14.

Fabiani, Iacopo, Nicola Riccardo Pugliese, Claudia De Angelis, et al.. (2015). Incremental value of 3D echocardiography and two-dimensional speckle tracking in the early detection of cardiotoxicity linked to chemotherapy and trastuzumab in patients with HER-2 positive breast cancer. Annals of Oncology. 26. vi16–vi16. 1 indexed citations

15.

Cortés, Javier, Eduard Vrdoljak, Fabio Puglisi, et al.. (2015). Abstract P3-06-08: Plasma (p) biomarker results from the TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative metastatic breast cancer (mBC). Cancer Research. 75(9_Supplement). P3–6. 3 indexed citations

16.

Salvadori, B., Maria A. Caligo, Andrea Fontana, et al.. (2015). Inherited mutations in breast cancer susceptibility genes among a triple negative breast cancer cohort unselected for family history of breast cancer. Annals of Oncology. 26. vi18–vi18. 1 indexed citations

17.

Orlandi, Paola, Andrea Fontana, Antonio Fioravanti, et al.. (2013). VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide. British Journal of Cancer. 109(4). 957–964. 24 indexed citations

18.

Allegrini, Giacomo, Teresa Di Desidero, Anna Fioravanti, et al.. (2012). Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis. 15(2). 275–286. 50 indexed citations

19.

Galli, Luca, Andrea Fontana, C. Galli, et al.. (2007). Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer. British Journal of Cancer. 97(12). 1613–1617. 4 indexed citations

20.

Bengala, Carmelo, Valentina Guarneri, Elisa Giovannetti, et al.. (2005). Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. British Journal of Cancer. 93(1). 35–40. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact